Phase
Condition
Metachromatic Leukodystrophy - Mld
Amyotrophic Lateral Sclerosis (Als)
Neurologic Disorders
Treatment
18F-AV-1451
Clinical Study ID
Ages 18-100 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS
Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
Participants will be 18 years of age or older
Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.
Participants must be willing and able to comply with scheduled visits and imaging procedures.
Subject is concurrently enrolled in centers UNICORN(842873) protocol.
INCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
Participants will be 18 years of age or older.
Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
Participants must be willing and able to comply with scheduled visits and imaging procedures.
Subject is concurrently enrolled in centers UNICORN(842873) protocol
EXCLUSION CRITERIA FOR ALL SUBJECTS
Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
ADDITIONAL EXCLUSION CRITERIA FOR HEALTHY CONTROL SUBJECTS
Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report.
Current use of psychoactive medications or substances per medical record review or self-report.
Study Design
Study Description
Connect with a study center
University of Pennsylvania
Philadelphia, Pennsylvania 19104
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.